Drug Discovery World

AUGUST 19, 2024

Researchers have uncovered how Flaviviruses like Dengue and Zika propagate, suggesting the possibility of new treatment strategies. Not only Dengue virus but also JEV and ZIKV have no medication for treatment.”

Treatment 148

Treatment Virus Vaccine Disease 148

Drug Discovery World

SEPTEMBER 4, 2024

The European Commission has granted orphan medicinal product designation (OMPD) to Cereno Scientific’s lead drug candidate CS1 for pulmonary arterial hypertension (PAH). The EU OMPD complements the orphan drug designation (ODD) granted by the US FDA in 2020, enhancing the protection and value of CS1 in these major markets.

Drugs 265

Drugs FDA Marketing Treatment 265

Drug Discovery World

APRIL 8, 2024

Scientists from Gwangju Institute of Science and Technology in Korea have discovered compound 11c, a potentially ground-breaking oral treatment for metabolic dysfunction-associated steatohepatitis. The post Potent drug candidate could transform liver disease treatment appeared first on Drug Discovery World (DDW).

Disease 130

Disease Treatment Pharmacokinetics Clinical Trials 130

Drug Discovery World

FEBRUARY 13, 2024

AM1476, a first-in-class, peripheral-acting serotonin receptor antagonist, has been granted US and EU Orphan Drug Designation as an anti-fibrotic treatment for systemic sclerosis. There are currently no treatments on the market that effectively stop or reverse scarring in both skin and lung tissue.

Disease 130

Disease Treatment Small Molecule Pharmacokinetics 130

Drug Discovery World

JUNE 26, 2024

Together with beLAB1407, we aim to develop a new treatment regime that could play a significant role in reducing one of the key factors in cardiovascular diseases.” The new treatment is anticipated to be able to help patients who are present at the hospital having survived a heart attack or stroke.

Treatment 148

Treatment Research Medical Schools RNA 148

Drug Discovery World

JULY 8, 2024

Biopharmaceutical company Syncromune has had its lead-candidate for the treatment of metastatic castrate-resistant prostate cancer (mCRPC) granted Fast Track designation by the FDA. Reece Armstrong, Editor, DDW The post FDA grants Fast Track designation to prostate cancer treatment appeared first on Drug Discovery World (DDW).

FDA 148

FDA Treatment Therapies Vaccine 148

Drug Discovery World

AUGUST 8, 2024

Additionally, MTX-463 was granted orphan drug and fast track designations by the FDA, underscoring the potential of WISP1 to address significant unmet needs in treating rare fibrotic diseases, including idiopathic pulmonary fibrosis (IPF).

Treatment 148

Treatment Pharmacokinetics Trials Disease 148

Drug Discovery World

JULY 5, 2024

Amgen has reported positive topline results from its randomised, double-blind, multicentre, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of its treatment for Immunoglobulin G4-related disease (IgG4-RD). ” Amgen is now planning to file for approval in the US following results on the MITIGATE study. .”

Treatment 148

Treatment Medical Schools Trials Clinical Trials 148

Drug Discovery World

JANUARY 16, 2023

The Phase II study used Alto’s Precision Psychiatry Platform to identify likely drug responders based on an understanding of biological heterogeneity in depression and ALTO-100’s novel mechanism. . The post Precision drug could redefine depression treatment appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Drugs Trials 130

Drug Discovery World

NOVEMBER 28, 2022

Novartis and Medicines for Malaria Venture (MMV) will progress ganaplacide/lumefantrine-solid dispersion formulation (SDF) into Phase III development for the treatment of patients with malaria due to Plasmodium falciparum. . The emergence of artemisinin resistance demands urgent action to develop new antimalarials.

Treatment 130

Treatment Clinical Trials Drugs Trials 130

Drug Discovery World

JUNE 19, 2024

Having a more detailed understanding of sepsis at a molecular level could identify those who would benefit from different therapies, helping to design rapid tests, organise clinical trials, and develop targeted treatments based on the individual immune response.

Immune Response 163

Immune Response Treatment Regulations Therapies 163

Drug Discovery World

JUNE 6, 2023

BenevolentAI, developers of AI that accelerates biopharma discovery, has delivered BEN-34712, its pre-clinical candidate for the potential treatment of amyotrophic lateral sclerosis (ALS). retinoic acid receptor alpha beta) biased agonist and will now enter investigational new drug (IND)-enabling studies.

Treatment 130

Treatment Drugs Clinical Development Therapies 130

Drug Discovery World

DECEMBER 2, 2022

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. The post UK approval for CBD pain treatment appeared first on Drug Discovery World (DDW).

Treatment 246

Treatment Clinical Trials Doctors Trials 246

Drug Discovery World

JANUARY 4, 2024

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business. In this episode, Megan Thomas is in conversation with Manfred Ruediger, CEO of Ariceum Therapeutics.

Treatment 163

Treatment Science Production Research 163

Drug Discovery World

JANUARY 18, 2024

Cancer immunotherapies, such as bispecific antibodies and CAR-T cell therapy, are rapidly moving into earlier lines of treatment in many tumour types, with these markets anticipated to grow to US$100bn+ (~35% CAGR) by 2030 3. In the US, the American Cancer Society estimates that there will be 24.6 million cases of cancer by 2030 1,2.

Treatment 163

Treatment Clinical Trials Immune Response Therapies 163

Drug Discovery World

FEBRUARY 29, 2024

For Rare Disease Day 2024, Diana Spencer provides a round-up of the latest breakthroughs in the treatment of rare disease. million from the French government to advance the development of a gene therapy for the treatment of cerebrotendinous xanthomatosis (CTX), a rare neurodegenerative disease.

Disease 130

Disease Treatment RNA Clinical Trials 130

Drug Discovery World

APRIL 24, 2024

Evotec and Variant Bio have announced a collaboration agreement to identify a best-in-class treatment for diseases caused by fibrosis. Despite the chronic nature of fibrotic conditions, widespread impact on various organs, and substantial disease burden, there is currently no curative treatment for these conditions.

Treatment 130

Treatment Small Molecule Clinical Development Disease 130

Drug Discovery World

FEBRUARY 19, 2024

PrecisionLife and the Metrodora Institute have agreed a partnership to jumpstart the diagnosis and treatment options for a range of complex, chronic diseases. In Metrodora we have a partner that is focused on the diagnosis and treatment of some of the most challenging and intractable diseases,” said Steve Gardner, PrecisionLife’s CEO.

Treatment 130

Treatment Clinical Trials Engineering Disease 130

Drug Discovery World

APRIL 11, 2023

Owing to the complexity of severe asthma, many patients have unclear or multiple drivers of airway inflammation resulting in some patients not responding to the current standard of treatment, and being at increased risk of asthma attacks, hospitalisations, and a poor quality of life 3,4,5,6. to 0.53; P<0.001).3 2005;172:149-160.

Treatment 246

Treatment Clinical Trials Trials Science 246

Drug Discovery World

MAY 6, 2024

It was also found that B cells which were consistently present in patients’ treatment had recognised cancer and had changed their genetic sequence to become more effective at identifying cancer. B cells which were only found in one tumour site were less likely to have diversified and did not perform effective cancer surveillance.

Treatment 130

Treatment Research Immune Response Virus 130

Drug Discovery World

MARCH 15, 2024

million to accelerate development of its lead drug candidates in the area of mitophagy, MTX325 and MTX652, through clinical trials. million raised to progress Parkinson’s treatment appeared first on Drug Discovery World (DDW). Mission Therapeutics has raised £25.2 ($32.1) Thanks to this additional £25.2m

Treatment 130

Treatment Clinical Trials Trials Disease 130

Drug Discovery World

JANUARY 4, 2024

AstraZeneca and Ionis’ Wainua (eplontersen) has been approved in the US for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults (hATTR-PN or ATTRv-PN). The post Wainua approval marks important milestone in amyloidosis treatment appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Trials FDA Disease 130

Drug Discovery World

DECEMBER 19, 2023

Despite VMS, or hot flushes, being a common symptom of menopause, until now, hormone replacement therapy (HRT) was the only treatment. The drug will be available from 5 January 2024, but only privately until the National Institute for Health and Care Excellence (NICE) makes a decision regarding its use on the NHS.

Treatment 148

Treatment Clinical Trials Regulations Therapies 148

DrugBank

JULY 8, 2024

Revolutionizing Treatment Through the Skin with Transdermal Drug Delivery Systems The human skin, often perceived as a passive barrier to the external environment, holds potential as a route for drug administration. This membrane regulates the diffusion of the drug from the reservoir into the skin.

Treatment 79

Treatment Drugs Clinical Trials Engineering 79

Drug Discovery World

JANUARY 31, 2024

Breye is developing novel, oral ophthalmology drugs fordiabetic retinopathy (DR) or age-related macular degeneration (AMD). The burden on patients with diabetic retinopathy is significant and those who experience vision loss and blindness face threats to their physical and mental health and overall quality of life.

Treatment 130

Treatment Clinical Trials Pharmacokinetics Trials 130

Drug Discovery World

JANUARY 17, 2024

Researchers in Japan have revealed the key underlying mechanisms in muscle atrophy, paving the way towards potential new treatments. Treatment with gamma-secretase inhibitors In healthy cells, there are regions in the ER called mitochondria-associated membranes (MAMs) that can be reversibly tethered to the mitochondria.

Treatment 130

Treatment Regulations Disease Research 130

Drug Discovery World

JUNE 28, 2023

Biopharmaceutical company InflaRx has launched Gohibic (vilobelimab) in the US for the treatment of Covid-19. Gohibic is currently the only drug directed against the complement factor C5a that is authorised for the treatment of certain critically ill Covid-19 patients. compared to placebo in the global data set.

Treatment 130

Treatment Virus FDA Trials 130

Drug Discovery World

MAY 15, 2024

Despite affecting such a large subset of diabetic patients, treatment options are limited to repeated, invasive intravitreal injections to the eye. Diabetic retinopathy – current treatments The journey for patients with DR is one of increasing severity and loss of vision. In 2019 there were >14.2

Disease 163

Disease Treatment Therapies Pharmaceuticals 163

Drug Discovery World

APRIL 4, 2024

The US Food and Drug Administration (FDA) has approved Vafseo (vadadustat) Tablets for the treatment of anaemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is now approved in 37 countries.

FDA Approval 130

FDA Approval FDA Disease Treatment 130

Drug Discovery World

NOVEMBER 29, 2023

Pharming’s investigational drug leniolisib is an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor. Leniolisib, marketed under the brand name Joenja in the US, received approval from the US Food and Drug Administration (FDA) for the treatment of APDS in adult and paediatric patients 12 years of age and older in March 2023.

Trials 130

Trials Treatment Clinical Trials FDA 130

Drug Discovery World

OCTOBER 4, 2023

Biotech company 4SC has announced positive new data for its treatment for patients with advanced-stage cutaneous T-cell lymphoma (CTCL). Findings from the RESMAIN study of 4SC’s resminostat (Kinselby) treatment show that the therapy can postpone disease progression in advanced CTCL.

Marketing 130

Marketing Treatment Therapies Disease 130

Drug Discovery World

OCTOBER 2, 2023

The European Commission (EC) has approved INAQOVI (oral decitabine and cedazuridine) as monotherapy for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for standard induction chemotherapy.

Treatment 130

Treatment Pharmacokinetics Clinical Trials Licensing 130

Drug Discovery World

FEBRUARY 1, 2024

At present there is no cure for CTX, only treatment to slow disease progression. The funding programme Vivet will use the funds to further develop its gene therapy product VTX-806 as an effective treatment option to stop or reverse disease progression over the long-term, or potentially cure CTX in patients.

Therapies 130

Therapies Treatment Disease Virus 130

Drug Discovery World

OCTOBER 11, 2023

Collaborators Boehringer Ingelheim and CDR-Life have commenced a Phase I evaluation of BI 771716, their antibody fragment-based treatment developed to preserve the vision of people with geographic atrophy (GA).

Clinical Trials 130

Clinical Trials Treatment Trials FDA Approval 130

Drug Discovery World

SEPTEMBER 14, 2023

You can listen below, or find The Drug Discovery World Podcast on Spotify , Google Play and Apple Podcasts. The post Delivering transformative treatments to cancer patients appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Engineering Science Research 130

Drug Discovery World

APRIL 5, 2024

Corteria Pharmaceuticals has initiated a Phase I study to evaluate the company’s first-in-class corticotropin-releasing hormone receptor 2 (CRF2) agonist, COR-1167, for the treatment of Worsening Heart Failure (WHF). The post Phase I study to evaluate treatment of worsening heart failure appeared first on Drug Discovery World (DDW).

Treatment 130

Treatment Pharmaceuticals Therapies Trials 130

Drug Discovery World

DECEMBER 23, 2022

A study by Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, has presented preliminary data from the first in human Phase I/II trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia (AML). . The data . Official comments

Treatment 130

Treatment Clinical Trials Drug Development Trials 130